214450.KQ KOE
PharmaResearch Co., Ltd.
1W: -5.1%
1M: -26.1%
3M: -16.5%
YTD: -9.1%
1Y: -53.9%
3Y: +135.9%
5Y: +247.8%
₩306,000.00 ($227.91)
-8500.00 (-2.70%)
Weekly Expected Move ±3.4%
₩285431
₩295716
₩306000
₩316284
₩326569
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$183.5B
+32.8% ▲
5Y CAGR: +41.5%
Capital Expenditures
$29.7B
+23.2% ▲
5Y CAGR: -3.4%
Free Cash Flow
$153.7B
+54.7% ▲
Dividends Paid
$11.4B
-13.3% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$10.3B
-89.5% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $46.7B | $40.6B | $77.3B | $88.9B | $165.1B |
| Depreciation & Amort. | $9.5B | $10.6B | $12.0B | $13.6B | $15.8B |
| Stock-Based Comp. | $0 | $506M | $657M | $659M | $0 |
| Change in Working Capital | $8.6B | -$10.5B | -$30.7B | $384M | -$24.7B |
| Other Non-Cash Items | $654M | $18.2B | $5.7B | $34.5B | $27.2B |
| Operating Cash Flow | $65.3B | $59.4B | $64.9B | $138.1B | $183.5B |
| — Investing Activities — | |||||
| Capital Expenditures | -$20.6B | -$17.8B | -$12.1B | -$36.4B | -$35.8B |
| Acquisitions (Net) | -$2.4B | $161M | -$4.0B | $1.6B | $180M |
| Investment Purchases | -$205.3B | -$308.1B | -$286.7B | -$423.6B | -$642.9B |
| Investment Sales | $135.0B | $313.0B | $258.8B | $242.8B | $517.8B |
| Other Investing | -$325M | $729M | -$745M | -$9.9B | $4.5B |
| Investing Cash Flow | -$93.8B | -$11.9B | -$44.7B | -$225.5B | -$156.2B |
| — Financing Activities — | |||||
| Net Debt Issuance | $49.4B | -$1.4B | -$16.8B | $10.4B | -$981M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$5.0B | -$6.3B | -$7.5B | -$10.1B | -$11.4B |
| Other Financing | -$26.4B | -$1.6B | -$2.0B | -$17.7B | -$2.9B |
| Financing Cash Flow | $43.0B | -$9.3B | -$26.0B | $182.6B | -$15.3B |
| Net Change in Cash | $15.0B | $31.3B | -$5.7B | $98.1B | $10.3B |
| Cash End of Period | $41.7B | $72.9B | $67.2B | $165.3B | $175.7B |
| Free Cash Flow | $41.5B | $41.6B | $51.7B | $99.4B | $153.7B |